The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis
Open accessAbstract
BACKGROUND: Fibroblast growth factor 23 (FGF-23) is a hormone that increases the rate of urinary excretion of phosphate and inhibits renal production of 1,25-dihydroxyvitamin D, thus helping to mitigate hyperphosphatemia in patients with kidney disease. Hyperphosphatemia and low 1,25-dihydroxyvitamin D levels are associated with mortality among patients with chronic kidney disease, but the effect of the level of FGF-23 on mortality is unknown. METHODS: We examined mortality according to serum phosphate levels in a prospective cohort of 10,044 patients who were beginning hemodialysis treatment and then analyzed FGF-23 levels and mortality in a nested case-control sample of 200 subjects who died and 200 who survived during the first year of hemodialysis treatment. We hypothesized that increased FGF-23 levels at the initiation of hemodialysis would be associated with increased mortality. RESULTS: Serum phosphate levels in the highest quartile (>5.5 mg per deciliter [1.8 mmol per liter]) were associated with a 20% increase in the multivariable adjusted risk of death, as compared with normal levels (3.5 to 4.5 mg per deciliter [1.1 to 1.4 mmol per liter]) (hazard ratio, 1.2; 95% confidence interval [CI], 1.1 to 1.4). Median C-terminal FGF-23 (cFGF-23) levels were significantly higher in case subjects than in controls (2260 vs. 1406 reference units per milliliter, P<0.001). Multivariable adjusted analyses showed that increasing FGF-23 levels were associated with a monotonically increasing risk of death when examined either on a continuous scale (odds ratio per unit increase in log-transformed cFGF-23 values, 1.8; 95% CI, 1.4 to 2.4) or in quartiles, with quartile 1 as the reference category (odds ratio for quartile 2, 1.6 [95% CI, 0.8 to 3.3]; for quartile 3, 4.5 [95% CI, 2.2 to 9.4]; and for quartile 4, 5.7 [95% CI, 2.6 to 12.6]). CONCLUSIONS: Increased FGF-23 levels appear to be independently associated with mortality among patients who are beginning hemodialysis treatment. Future studies might investigate whether FGF-23 is a potential biomarker that can be used to guide strategies for the management of phosphorus balance in patients with chronic kidney disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis
Block, G. A., Klassen, P. S., Lazarus, J. M., Ofsthun, N., Lowrie, E. G., & Chertow, G. M. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000133041.27682.a2 · Cited by 2,687
Shimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., Tomizuka, K., & Yamashita, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19081 · Cited by 1,596
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23
White, K. E., Evans, W. E., O'Riordan, J. L. H., Speer, M. C., Econs, M. J., Lorenz-Depiereux, B., Grabowski, M., Meitinger, T., & Strom, T. M. (2000) · Nature Genetics · doi:10.1038/81664 · Cited by 1,528
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia
Shimada, T., Mizutani, S., Muto, T., Yoneya, T., Hino, R., Takeda, S., Takeuchi, Y., Fujita, T., Fukumoto, S., & Yamashita, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.101545198 · Cited by 1,457
Serum Phosphate Levels and Mortality Risk among People with Chronic Kidney Disease
Kestenbaum, B., Sampson, J. N., Rudser, K. D., Patterson, D. J., Seliger, S. L., Young, B., Sherrard, D. J., & Andress, D. L. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004070602 · Cited by 1,226
The parathyroid is a target organ for FGF23 in rats
Ben-Dov, I. Z., Galitzer, H., Lavi-Moshayoff, V., Goetz, R., Kuro-o, M., Mohammadi, M., Sirkis, R., Naveh-Many, T., & Silver, J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32409 · Cited by 951
Survival of Patients Undergoing Hemodialysis with Paricalcitol or Calcitriol Therapy
Teng, M., Wolf, M., Lowrie, E., Ofsthun, N., Lazarus, J. M., & Thadhani, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022536 · Cited by 927
Self-citationGutierrez, O., Isakova, T., Rhee, E., Shah, A., Holmes, J., Collerone, G., Ju[Combining Diaeresis]ppner, H., & Wolf, M. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010052 · Cited by 921
Self-citationFibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked Hypophosphatemia
Jonsson, K. B., Zahradnik, R., Larsson, T., White, K. E., Sugimoto, T., Imanishi, Y., Yamamoto, T., Hampson, G., Koshiyama, H., Ljunggren, Ö., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020881 · Cited by 914
Self-citation
Cited by
FGF23 induces left ventricular hypertrophy
Faul, C., Amaral, A. P., Oskouei, B., Hu, M.-C., Sloan, A., Isakova, T., Gutiérrez, O. M., Aguillon-Prada, R., Lincoln, J., Hare, J. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46122 · Cited by 2,027
Self-citationThe FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
Isakova, T., on behalf of the Chronic Renal Insufficiency Cohort (CRIC) Study Group, Wahl, P., Vargas, G. S., Gutiérrez, O. M., Scialla, J., Xie, H., Appleby, D., Nessel, L., Bellovich, K., et al. (2011) · Kidney International · doi:10.1038/ki.2011.47 · Cited by 1,266
Self-citationIsakova, T. (2011) · JAMA · doi:10.1001/jama.2011.826 · Cited by 1,020
Self-citationEffect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis
The EVOLVE Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205624 · Cited by 971
Herzog, C. A., Asinger, R. W., Berger, A. K., Charytan, D. M., Díez, J., Hart, R. G., Eckardt, K.-U., Kasiske, B. L., McCullough, P. A., Passman, R. S., et al. (2011) · Kidney International · doi:10.1038/ki.2011.223 · Cited by 922
Calcium metabolism in health and disease
Peacock, M. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05910809 · Cited by 886
Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease
Gutiérrez, O. M., Januzzi, J. L., Isakova, T., Laliberte, K., Smith, K., Collerone, G., Sarwar, A., Hoffmann, U., Coglianese, E., Christenson, R., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.844506 · Cited by 837
Self-citationEpidemiology and risk of cardiovascular disease in populations with chronic kidney disease
Matsushita, K., Ballew, S. H., Wang, A. Y.-M., Kalyesubula, R., Schaeffner, E., & Agarwal, R. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00616-6 · Cited by 670
Nutritional Management of Chronic Kidney Disease
Kalantar-Zadeh, K., & Fouque, D. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1700312 · Cited by 636
Regulation and Function of the FGF23/Klotho Endocrine Pathways
Martin, A., David, V., & Quarles, L. D. (2012) · Physiological Reviews · doi:10.1152/physrev.00002.2011 · Cited by 594
Yahagi, K., Kolodgie, F. D., Lutter, C., Mori, H., Romero, M. E., Finn, A. V., & Virmani, R. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.306256 · Cited by 573
Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy
Grabner, A., Amaral, A. P., Schramm, K., Singh, S., Sloan, A., Yanucil, C., Li, J., Shehadeh, L. A., Hare, J. M., David, V., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.09.002 · Cited by 541
Self-citationInflammation and functional iron deficiency regulate fibroblast growth factor 23 production
David, V., Martin, A., Isakova, T., Spaulding, C., Qi, L., Ramirez, V., Zumbrennen-Bullough, K. B., Sun, C. C., Lin, H. Y., Babitt, J. L., et al. (2016) · Kidney International · doi:10.1038/ki.2015.290 · Cited by 494
Self-citationLim, K., Lu, T.-S., Molostvov, G., Lee, C., Lam, F. T., Zehnder, D., & Hsiao, L.-L. (2012) · Circulation · doi:10.1161/circulationaha.111.053405 · Cited by 461
Endocrine functions of bone in mineral metabolism regulation
Quarles, L. D. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36479 · Cited by 459
Hayati Rezvan, P., Lee, K. J., & Simpson, J. A. (2015) · BMC Medical Research Methodology · doi:10.1186/s12874-015-0022-1 · Cited by 459
Parker, B. D., Schurgers, L. J., Brandenburg, V. M., Christenson, R. H., Vermeer, C., Ketteler, M., Shlipak, M. G., Whooley, M. A., & Ix, J. H. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-10-201005180-00004 · Cited by 457
The FGF23–Klotho axis: endocrine regulation of phosphate homeostasis
Razzaque, M. S. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.196 · Cited by 448
FGF-23 Associates with Death, Cardiovascular Events, and Initiation of Chronic Dialysis
Kendrick, J., Cheung, A. K., Kaufman, J. S., Greene, T., Roberts, W. L., Smits, G., & Chonchol, M. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010121224 · Cited by 448
Fibroblast Growth Factor-23 and Cardiovascular Events in CKD
Scialla, J. J., Xie, H., Rahman, M., Anderson, A. H., Isakova, T., Ojo, A., Zhang, X., Nessel, L., Hamano, T., Grunwald, J. E., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013050465 · Cited by 445
Self-citationLavi-Moshayoff, V., Wasserman, G., Meir, T., Silver, J., & Naveh-Many, T. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00360.2010 · Cited by 441
Wolf, M., Koch, T. A., & Bregman, D. B. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1923 · Cited by 430
Self-citationTherapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Degirolamo, C., Sabbà, C., & Moschetta, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.9 · Cited by 424
Shalhoub, V., Shatzen, E. M., Ward, S. C., Davis, J., Stevens, J., Bi, V., Renshaw, L., Hawkins, N., Wang, W., Chen, C., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61405 · Cited by 413
Clinical Practice Guideline for the Management of Chronic Kidney Disease‐Mineral and Bone Disorder
Fukagawa, M., Yokoyama, K., Koiwa, F., Taniguchi, M., Shoji, T., Kazama, J. J., Komaba, H., Ando, R., Kakuta, T., Fujii, H., et al. (2013) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12058 · Cited by 402
Biomarkers in chronic kidney disease, from kidney function to kidney damage
Lopez-Giacoman, S. (2015) · World Journal of Nephrology · doi:10.5527/wjn.v4.i1.57 · Cited by 392
Update on fibroblast growth factor 23 in chronic kidney disease
Wolf, M. (2012) · Kidney International · doi:10.1038/ki.2012.176 · Cited by 391
Self-citationCirculating fibroblast growth factor-23 is associated with vascular dysfunction in the community
Mirza, M. A. I., Larsson, A., Lind, L., & Larsson, T. E. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.01.001 · Cited by 386
Phosphorus Binders and Survival on Hemodialysis
Isakova, T., Gutie[Combining Acute Accent]rrez, O. M., Chang, Y., Shah, A., Tamez, H., Smith, K., Thadhani, R., & Wolf, M. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008060609 · Cited by 375
Self-citationSingh, S., Grabner, A., Yanucil, C., Schramm, K., Czaya, B., Krick, S., Czaja, M. J., Bartz, R., Abraham, R., Di Marco, G. S., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.05.019 · Cited by 360
Self-citationEarly Control of PTH and FGF23 in Normophosphatemic CKD Patients: A New Target in CKD-MBD Therapy?
Oliveira, R. B., Cancela, A. L. E., Graciolli, F. G., Dos Reis, L. M., Draibe, S. A., Cuppari, L., Carvalho, A. B., Jorgetti, V., Canziani, M. E., & Moysés, R. M. A. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05420709 · Cited by 357
Jean, G., Terrat, J.-C., Vanel, T., Hurot, J.-M., Lorriaux, C., Mayor, B., & Chazot, C. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp191 · Cited by 351
Mirza, M. A. I., Larsson, A., Melhus, H., Lind, L., & Larsson, T. E. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.05.013 · Cited by 341
Oral Phosphate Binders in Patients with Kidney Failure
Tonelli, M., Pannu, N., & Manns, B. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912522 · Cited by 339
Genovese, F., Manresa, A. A., Leeming, D. J., Karsdal, M. A., & Boor, P. (2014) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-7-4 · Cited by 337
Fibroblast growth factor 23 is not associated with and does not induce arterial calcification
Scialla, J. J., Lau, W. L., Reilly, M. P., Isakova, T., Yang, H.-Y., Crouthamel, M. H., Chavkin, N. W., Rahman, M., Wahl, P., Amaral, A. P., et al. (2013) · Kidney International · doi:10.1038/ki.2013.3 · Cited by 333
Self-citationIx, J. H., Katz, R., Kestenbaum, B. R., de Boer, I. H., Chonchol, M., Mukamal, K. J., Rifkin, D., Siscovick, D. S., Sarnak, M. J., & Shlipak, M. G. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.040 · Cited by 324
Sullivan, C., Sayre, S. S., Leon, J. B., Machekano, R., Love, T. E., Porter, D., Marbury, M., & Sehgal, A. R. (2009) · JAMA · doi:10.1001/jama.2009.96 · Cited by 319
Forging Forward with 10 Burning Questions on FGF23 in Kidney Disease
Wolf, M. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009121293 · Cited by 308
Self-citationMoe, S. M., Chertow, G. M., Parfrey, P. S., Kubo, Y., Block, G. A., Correa-Rotter, R., Drüeke, T. B., Herzog, C. A., London, G. M., Mahaffey, K. W., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013876 · Cited by 302
Role of FGF23 in vitamin D and phosphate metabolism: Implications in chronic kidney disease
Quarles, L. D. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.02.027 · Cited by 298
Gutiérrez, O. M., Farwell, W. R., Kermah, D., & Taylor, E. N. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1383-2 · Cited by 296
Self-citationChronic Kidney Disease: A Clinical Model of Premature Aging
Stenvinkel, P., & Larsson, T. E. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.11.051 · Cited by 296
Elevated Fibroblast Growth Factor 23 is a Risk Factor for Kidney Transplant Loss and Mortality
Wolf, M., Molnar, M. Z., Amaral, A. P., Czira, M. E., Rudas, A., Ujszaszi, A., Kiss, I., Rosivall, L., Kosa, J., Lakatos, P., et al. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010080894 · Cited by 290
Self-citationEndothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update
Roumeliotis, S., Mallamaci, F., & Zoccali, C. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082359 · Cited by 284
de Borst, M. H., Vervloet, M. G., ter Wee, P. M., & Navis, G. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010121251 · Cited by 282
Relation Between Alkaline Phosphatase, Serum Phosphate, and All-Cause or Cardiovascular Mortality
Tonelli, M., Curhan, G., Pfeffer, M., Sacks, F., Thadhani, R., Melamed, M. L., Wiebe, N., & Muntner, P. (2009) · Circulation · doi:10.1161/circulationaha.109.851873 · Cited by 280
Self-citationFGF23 signaling impairs neutrophil recruitment and host defense during CKD
Rossaint, J., Oehmichen, J., Van Aken, H., Reuter, S., Pavenstädt, H. J., Meersch, M., Unruh, M., & Zarbock, A. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83470 · Cited by 276
Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism
Quarles, L. D. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.218 · Cited by 269
Fibroblast Growth Factor 23 and Inflammation in CKD
Munoz Mendoza, J., Isakova, T., Ricardo, A. C., Xie, H., Navaneethan, S. D., Anderson, A. H., Bazzano, L. A., Xie, D., Kretzler, M., Nessel, L., et al. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.13281211 · Cited by 267
Self-citationStat3 Activation Links a C/EBPδ to Myostatin Pathway to Stimulate Loss of Muscle Mass
Zhang, L., Pan, J., Dong, Y., Tweardy, D. J., Dong, Y., Garibotto, G., & Mitch, W. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.07.012 · Cited by 263
Drechsler, C., Pilz, S., Obermayer-Pietsch, B., Verduijn, M., Tomaschitz, A., Krane, V., Espe, K., Dekker, F., Brandenburg, V., Marz, W., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq246 · Cited by 258
Effects of Dietary Phosphate and Calcium Intake on Fibroblast Growth Factor-23
Vervloet, M. G., van Ittersum, F. J., Büttler, R. M., Heijboer, A. C., Blankenstein, M. A., & ter Wee, P. M. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04730510 · Cited by 218
Jüppner, H. (2011) · Kidney International · doi:10.1038/ki.2011.27 · Cited by 191
Self-citationOverview of the FGF23-Klotho axis
Kuro-o, M. (2010) · Pediatric Nephrology · doi:10.1007/s00467-009-1260-4 · Cited by 162
“In addition, epidemiological studies have indicated that high serum FGF23 levels are associated with poor prognosis in patients undergoing dialysis [83].”
BackgroundDussold, C., Gerber, C., White, S., Wang, X., Qi, L., Francis, C., Capella, M., Courbon, G., Wang, J., Li, C., et al. (2019) · Bone Research · doi:10.1038/s41413-019-0051-1 · Cited by 96
Self-citationThe Structural Biology of the FGF19 Subfamily
Beenken, A., & Mohammadi, M. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-0887-1_1 · Cited by 93
Fibroblast Growth Factor 23 and Risk of Incident Stroke in Community-Living Adults
Panwar, B., Jenny, N. S., Howard, V. J., Wadley, V. G., Muntner, P., Kissela, B. M., Judd, S. E., & Gutiérrez, O. M. (2015) · Stroke · doi:10.1161/strokeaha.114.007489 · Cited by 65
Self-citationTurner, M. E., Beck, L., Hill Gallant, K. M., Chen, Y., Moe, O. W., Kuro-o, M., Moe, S. M., & Aikawa, E. (2024) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.123.319198 · Cited by 54
T wave morphology changes during hemodialysis
Poulikakos, D., Banerjee, D., & Malik, M. (2013) · Journal of Electrocardiology · doi:10.1016/j.jelectrocard.2013.07.006 · Cited by 13
Egli-Spichtig, D., Hamid, A. K., Arroyo, E. M. P., Ketteler, M., Wiecek, A., Rosenkranz, A. R., Pasch, A., Lorenz, H., Hellmann, B., Karus, M., et al. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad040 · Cited by 9
Metadata
- Authors
- Gutiérrez, O. M., Mannstadt, M., Isakova, T., Rauh-Hain, J. A., Tamez, H., Shah, A., Smith, K., Lee, H., Thadhani, R., Jüppner, H., & Wolf, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-08-07
- Volume
- 359
- Issue
- 6
- Pages
- 584-592
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1977645780
- Cited by
- 1,727
- References
- 37
- FWCI
- 75.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.